MX2022008770A - Muteinas de la il2. - Google Patents
Muteinas de la il2.Info
- Publication number
- MX2022008770A MX2022008770A MX2022008770A MX2022008770A MX2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A MX 2022008770 A MX2022008770 A MX 2022008770A
- Authority
- MX
- Mexico
- Prior art keywords
- muteins
- treatment
- human disease
- present disclosures
- disclosures
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a muteínas de la IL2 y sus usos en el tratamiento de enfermedades humanas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062960847P | 2020-01-14 | 2020-01-14 | |
PCT/US2021/013514 WO2021146481A1 (en) | 2020-01-14 | 2021-01-14 | Il2 muteins |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008770A true MX2022008770A (es) | 2022-10-07 |
Family
ID=76863259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008770A MX2022008770A (es) | 2020-01-14 | 2021-01-14 | Muteinas de la il2. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230210951A1 (es) |
EP (1) | EP4090354A4 (es) |
JP (1) | JP2023510871A (es) |
KR (1) | KR20220127866A (es) |
CN (1) | CN115066253A (es) |
AU (1) | AU2021207661A1 (es) |
CA (1) | CA3166009A1 (es) |
IL (1) | IL294070A (es) |
MX (1) | MX2022008770A (es) |
WO (1) | WO2021146481A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
AU2017359172A1 (en) * | 2016-11-08 | 2019-05-16 | Delinia, Inc. | IL-2 variants for the treatment of autoimmune diseases |
JP7269249B2 (ja) * | 2017-11-10 | 2023-05-08 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Il2rベータ/共通ガンマ鎖抗体 |
JP2021528105A (ja) * | 2018-06-22 | 2021-10-21 | キュージーン インコーポレイテッドCugene Inc. | インターロイキン−2バリアントおよびその使用方法 |
-
2021
- 2021-01-14 JP JP2022542897A patent/JP2023510871A/ja active Pending
- 2021-01-14 WO PCT/US2021/013514 patent/WO2021146481A1/en unknown
- 2021-01-14 KR KR1020227027688A patent/KR20220127866A/ko unknown
- 2021-01-14 IL IL294070A patent/IL294070A/en unknown
- 2021-01-14 US US17/785,786 patent/US20230210951A1/en active Pending
- 2021-01-14 AU AU2021207661A patent/AU2021207661A1/en active Pending
- 2021-01-14 CA CA3166009A patent/CA3166009A1/en active Pending
- 2021-01-14 MX MX2022008770A patent/MX2022008770A/es unknown
- 2021-01-14 CN CN202180009469.XA patent/CN115066253A/zh active Pending
- 2021-01-14 EP EP21741554.6A patent/EP4090354A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021207661A1 (en) | 2022-07-21 |
EP4090354A4 (en) | 2024-05-22 |
CN115066253A (zh) | 2022-09-16 |
KR20220127866A (ko) | 2022-09-20 |
IL294070A (en) | 2022-08-01 |
EP4090354A1 (en) | 2022-11-23 |
CA3166009A1 (en) | 2021-07-22 |
US20230210951A1 (en) | 2023-07-06 |
JP2023510871A (ja) | 2023-03-15 |
WO2021146481A1 (en) | 2021-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
MX2022008770A (es) | Muteinas de la il2. | |
MX2021010323A (es) | Compuestos bicíclicos de heterociclilo y usos de este. | |
Gileva et al. | Hirudotherapy | |
Lou et al. | Analysis of the effectiveness of basic fibroblast growth factor treatment on traumatic perforation of the tympanic membrane at different time points | |
NO20071238L (no) | Fremgangsmater for leging av skader ved human IL-18 administrering | |
EA200870108A1 (ru) | Мутанты фсг | |
WO2022043273A3 (en) | Oral care composition comprising a fructanase | |
PT1585513E (pt) | Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia | |
EP4067504A4 (en) | USE OF SYNAPTOTAGMINE-7 IN THE DIAGNOSIS AND TREATMENT OF BIPOLAR DISORDER | |
Woolf | My honest note to hospital staff changed everything—combining healing for body and mind | |
HUP0301451A2 (hu) | CGMP PDE5 inhibitorok alkalmazása perifériás érbetegségek, perifériás neuropátiák és autonóm neuropátiák kezelésére szolgáló gyógyszerkészítmények elżállítására | |
Castillo et al. | Reply to:“Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need” | |
Pasek et al. | Wound treatment after congenital syndactyly separation with 100% oxygen therapy: A case report | |
WO2022240804A3 (en) | Methods of treating sickle cell disorder and related conditions | |
Baxi et al. | Immediate Effects of Kinesio Taping on Lung Functions, Chest Expansion and Dyspnoea in COPD Patients. | |
Nagarajan et al. | Effectiveness of varmam therapy in patchavatham (hemiplegia)-a case report | |
Koren et al. | Unusual primary and secondary facial blast injuries | |
ATE466587T1 (de) | Valeriana officinalis extrakt zur behandlung von schlafapnoe oder hypopnoe | |
Thenmozhi et al. | Hyperbaric oxygen therapy: Therapeutic role in various cases–A case series | |
Drouin et al. | A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis | |
MX2023000732A (es) | Anticuerpos anti- alfa-4-beta-7. | |
TWD231873S (zh) | 手持按摩器 | |
RU2009119225A (ru) | Способ лечения и профилактики кокцидиозов норок | |
Pasek et al. | Possibilities of physical medicine in the treatment of wound of tarsal joint |